Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD), a drug-discovery approach that uses small molecules to tag and eliminate disease-causing proteins. Its analyst price target profile reflects a pipeline story rather than a profitability story.
Across the 14 analysts tracked, current 12-month targets span from a low of $25 (Wells Fargo, which holds a Hold rating) to a high of $45, with Stifel at $41 and Morgan Stanley at $38 near the top. The arithmetic mean of the verified targets sits around $34.5, which rounds to a clean $35 central target. Most firms rate the stock Buy, Outperform, or Overweight.
Recent revisions illustrate how sentiment has shifted. After the fiscal third-quarter results (the first reported quarter following the Roche deal close), RBC Capital lowered its target to $35 from $36 and Truist lowered to $33 from $34, while H.C. Wainwright raised to $36, Oppenheimer raised to $32 from $28, Baird raised to $36 from $33, and Morgan Stanley raised to $38 from $36. The recurring rationale is that the Roche collaboration de-risks bexobrutideg and extends the company's financial runway, while offering optionality into upcoming STAT6 degrader data readouts.
With shares trading near $24.93 after a close at that level on October 19, 2026, NRIX would need to rise roughly 40% to reach the $35 central target — a substantial move by any standard. The stock has already rallied sharply from a 52-week low near $9.7 and sits below its 52-week high near $28.2, with a market capitalization of about $2.7 billion.
Reaching $35 is not a question of quarterly earnings math; Nurix remains unprofitable on an operating basis. The path depends on continued clinical progress for bexobrutideg (NX-5948), its oral BTK degrader in late-stage development for chronic lymphocytic leukemia (CLL) and other B-cell malignancies, expansion into autoimmune indications, and successful advancement of partnered programs.
The Roche agreement is the linchpin of the bull case. The roughly $700 million upfront payment, a 50% U.S. profit share, and 60% Roche-funded global development validate the bexobrutideg program and meaningfully de-risk its funding. A cash position of about $1.1 billion as of August 31, 2026 supports a multi-year runway without immediate dilution.
Beyond Roche, Nurix maintains collaborations with Sanofi (STAT6 degrader), Gilead (IRAK4 degrader), and Pfizer, providing milestone optionality. Early bexobrutideg data have shown encouraging response rates in heavily pretreated CLL patients, and analyst price targets have trended upward through 2026 as firms update models for the Roche economics. Positive Phase 3 data, autoimmune proof-of-concept results, or new partnership milestones could each justify a higher stock forecast.
The principal risk is clinical failure. Bexobrutideg must demonstrate superiority or compelling differentiation in a competitive BTK space that includes approved agents and rival degraders from companies such as BeiGene. Any setback in the Phase 3 program, a safety signal, or a regulatory delay could compress the valuation quickly.
Nurix also continues to post operating losses, and future revenue depends heavily on milestone payments and partnership economics rather than recurring product sales. Valuation remains rich by traditional metrics, the stock is volatile with a beta above 1.8, and recent insider selling has added a cautionary signal. A broad rotation out of biotechnology or rising risk aversion could weigh on the share price regardless of company-specific progress.
The 52-week high near $28.2 is the most relevant resistance level; a sustained move toward $35 would require a breakout to new highs well above that zone. On the downside, the stock held support near $22 following the fiscal third-quarter results, and the psychological $20 level sits just below. The $35 target therefore represents an all-time-high-adjacent objective, making the prior high an important area to watch for confirmation of momentum.
Analyst price targets typically reflect a roughly 12-month horizon, though biotech targets can shift materially on clinical data. Key catalysts include upcoming STAT6 degrader data readouts, further bexobrutideg Phase 3 updates and autoimmune expansion plans, partnership milestone announcements, and the next quarterly earnings report. Analyst revisions, insider transactions, and broader biotech sentiment will also influence the trajectory toward any stock price target.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool helps traders screen for opportunities, keep an eye on existing positions, and identify shifting trends more efficiently than manual scanning. For investors following NRIX or building a watchlist across sectors, the signals offer a structured way to complement fundamental research with data-driven timing insight.
The $35 central target — the average of current analyst price targets, rounded from about $34.5 — sits roughly 40% above the latest price and reflects a pipeline-led, de-risked bull case anchored by the Roche partnership. Support comes from the bexobrutideg clinical program, a strengthened balance sheet, and additional collaboration optionality. Against that, clinical execution risk, a competitive BTK landscape, persistent operating losses, and a valuation that already prices in meaningful success stand as the principal obstacles. The wide $25-to-$45 analyst range underscores genuine disagreement about how much of the opportunity is already reflected in the stock. Whether NRIX reaches $35 will most likely hinge on clinical data and partnership milestones rather than near-term earnings, and investors should monitor those catalysts closely rather than treat the figure as a guarantee.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NRIX has been loosely correlated with KYMR. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NRIX jumps, then KYMR could also see price increases.
| Ticker / NAME | Correlation To NRIX | 1D Price Change % | ||
|---|---|---|---|---|
| NRIX | 100% | +0.47% | ||
| KYMR - NRIX | 60% Loosely correlated | -0.33% | ||
| GPCR - NRIX | 49% Loosely correlated | -0.59% | ||
| PRME - NRIX | 45% Loosely correlated | +2.48% | ||
| DYN - NRIX | 45% Loosely correlated | +4.34% | ||
| AGIO - NRIX | 44% Loosely correlated | +4.17% | ||
More | ||||